Testosterone enanthate

Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Conference

Retrieved on: 
Wednesday, July 7, 2021
Steroids, Organic compounds, Chemical compounds, Androstanes, Ketones, Testosterone enanthate, Teva Pharmaceuticals, Testosterone, Sumatriptan, Ladenburg Thalmann, Pharma

EWING, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference.

Key Points: 
  • EWING, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference.
  • Details of the presentation are as follows:
    A live webcast of the presentation will be available under the For Investors section of the Antares Pharma website at www.antarespharma.com.
  • Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas such as urology and endocrinology.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

Antares Pharma to Present at the Raymond James Human Health Innovations Conference

Retrieved on: 
Tuesday, June 15, 2021
Steroids, Drugs, Chemical compounds, Androstanes, Triptans, Ketones, Testosterone enanthate, Testosterone, Sumatriptan, Teva Pharmaceuticals, Subcutaneous, Forward-looking statement

EWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Raymond James Human Health Innovations Conference.

Key Points: 
  • EWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Raymond James Human Health Innovations Conference.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

Antares Pharma to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Drugs, Steroids, Organic compounds, Androstanes, Ketones, Testosterone enanthate, Hepatotoxins, Teva Pharmaceuticals, Immunosuppressants, Sumatriptan, Testosterone, Subcutaneous

A live webcast of the presentation will be available under the For Investors section of the Antares Pharma website at www.antarespharma.com.

Key Points: 
  • A live webcast of the presentation will be available under the For Investors section of the Antares Pharma website at www.antarespharma.com.
  • Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas such as urology and endocrinology.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

Antares Pharma Reports First Quarter 2021 Financial and Operating Results

Retrieved on: 
Thursday, May 6, 2021
Steroids, Receptor agonists, Androstanes, Organic compounds, Triptans, Ketones, Testosterone, Testosterone enanthate, Sumatriptan, Subcutaneous, Forward-looking statement, XC2

Furthermore, our commercial organization implemented an enhanced targeting strategy that reinforces the expansion opportunities for XYOSTED and the relaunch of NOCDURNA.

Key Points: 
  • Furthermore, our commercial organization implemented an enhanced targeting strategy that reinforces the expansion opportunities for XYOSTED and the relaunch of NOCDURNA.
  • Antares Pharma\xe2\x80\x99s FDA-approved products include XYOSTED\xc2\xae (testosterone enanthate) injection, OTREXUP\xc2\xae (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.
  • The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release.

Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual Annual Meeting

Retrieved on: 
Monday, May 3, 2021
Steroids, Receptor agonists, Androstanes, Organic compounds, Triptans, Ketones, Testosterone enanthate, Testosterone, Sumatriptan, Subcutaneous, Autoinjector, Teva Pharmaceuticals

Vogiatzi commented, \xe2\x80\x9cWe were pleased to be able to share this novel data extrapolation with our colleagues and peers.

Key Points: 
  • Vogiatzi commented, \xe2\x80\x9cWe were pleased to be able to share this novel data extrapolation with our colleagues and peers.
  • There are currently no approved autoinjectors to deliver subcutaneous testosterone in this medically underserved population.
  • Antares Pharma\xe2\x80\x99s FDA-approved products include XYOSTED\xc2\xae (testosterone enanthate) injection, OTREXUP\xc2\xae (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

Antares Pharma to Participate in the 7th Annual Truist Securities 2021 Life Sciences Summit

Retrieved on: 
Wednesday, April 28, 2021
Steroids, Organic compounds, Androstanes, Chemical compounds, Ketones, Testosterone, Testosterone enanthate, XC2, Forward-looking statement, Subcutaneous, Ferring Pharmaceuticals, Sumatriptan

Antares Pharma\xe2\x80\x99s FDA-approved products include XYOSTED\xc2\xae (testosterone enanthate) injection, OTREXUP\xc2\xae (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

Key Points: 
  • Antares Pharma\xe2\x80\x99s FDA-approved products include XYOSTED\xc2\xae (testosterone enanthate) injection, OTREXUP\xc2\xae (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • The Company also markets NOCDURNA\xc2\xae (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.\nThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.
  • The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release.

Antares Pharma to Report First Quarter 2021 Financial and Operating Results

Retrieved on: 
Tuesday, April 27, 2021
Drugs, Steroids, Organic compounds, Androstanes, Ketones, Testosterone, XC2, Testosterone enanthate, Subcutaneous, Sumatriptan, Methotrexate, Teva Pharmaceuticals

b'EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (\xe2\x80\x9cthe Company\xe2\x80\x9d), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the market opens.\nAntares\xc2\xa0will host a conference call on\xc2\xa0Thursday, May 6, 2021 at\xc2\xa08:30am ET\xc2\xa0to discuss the results.

Key Points: 
  • b'EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (\xe2\x80\x9cthe Company\xe2\x80\x9d), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the market opens.\nAntares\xc2\xa0will host a conference call on\xc2\xa0Thursday, May 6, 2021 at\xc2\xa08:30am ET\xc2\xa0to discuss the results.
  • The dial-in numbers are (800) 367-2403 for domestic callers and (334) 777-6978 for international callers.
  • Antares Pharma\xe2\x80\x99s FDA-approved products include XYOSTED\xc2\xae (testosterone enanthate) injection, OTREXUP\xc2\xae (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

Sizeable Numbers to Endorse Benefits and Efficacy of Umbrella of Hormone Replacement Therapies underscores Growth in Testosterone Replacement Therapy Market, Valuation Projected to touch US $ 2.2 Bn by 2027, Says TMR

Retrieved on: 
Thursday, April 22, 2021
Steroids, Organ systems, Androstanes, Organic compounds, Testosterone, Enones, Estrogens, GABAA receptor positive allosteric modulators, Androgen replacement therapy, Hypogonadism, Testosterone cypionate, Testosterone enanthate

b'ALBANY, N.Y., April 22, 2021 /PRNewswire/ -- Testosterone replacement therapy is widely used treatment for men with symptomatic hypogonadism.

Key Points: 
  • b'ALBANY, N.Y., April 22, 2021 /PRNewswire/ -- Testosterone replacement therapy is widely used treatment for men with symptomatic hypogonadism.
  • The benefits of testosterone replacement therapy manifest as increased energy and libido level, improved bone density and strength, improved muscle strength, and cardioprotective effects.
  • Thus, the positive results of such therapy has led to a substantial demand for testosterone replacement therapy for men with symptomatic hypogonadism, though there is insufficient data for long-term efficacy and safety of the therapy.\nNonetheless, the beneficial effects of testosterone replacement therapy is rarely disputed instead widely publicized that marks bright prospects for the testosterone replacement therapy market.
  • For example, in the recent past, the U.S. FDA provided approval for a generic testosterone gel to use for testosterone replacement therapy for men with symptomatic hypogonadism.

Antares Pharma to Present at Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 24, 2021
Drugs, Steroids, Health care, Androstanes, Dosage forms, Ketones, Testosterone enanthate, Transgender hormone therapy, Teva Pharmaceuticals, Sumatriptan, Testosterone, Ferring Pharmaceuticals

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.

Key Points: 
  • Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • The Company also markets NOCDURNA (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

Antares Pharma to Participate in the SVB Leerink 10th Annual Virtual Global Healthcare Conference

Retrieved on: 
Wednesday, February 17, 2021
Steroids, Organic compounds, Drugs, Androstanes, Ketones, Testosterone enanthate, Teva Pharmaceuticals, Sumatriptan, SVB Leerink, Testosterone

EWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to participate and host investor meetings at the SVB Leerink 10th Annual Virtual Global Healthcare Conference being held on February 22-26, 2021.

Key Points: 
  • EWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to participate and host investor meetings at the SVB Leerink 10th Annual Virtual Global Healthcare Conference being held on February 22-26, 2021.
  • Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.